We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
York Pharma | LSE:YRK | London | Ordinary Share | GB00B00QHC86 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.25 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
13/5/2009 12:56 | Good news at least. What the CEO is saying is accept the offer as shareholders otherwise he cant guarantee a satisfactory return to shareholders and they will need to raise funds. Well if its a case of take the offer or decline it I will take it as something is better than nothing. I bought quite low so am okay but feel for those who have put huge sums in over past few years, but at least this way you do get something back if takeover goes ahead. The new CEO has a large shareholding so will obvioulsy do His best to get as much as possible for shareholders. TIDMYRK RNS Number : 1382S York Pharma plc 12 May 2009 ? 12 May 2009 York Pharma plc (YRK.L) ("York" or the "Company") Restructure update and divestment of French subsidiary In January 2009, York announced that its newly appointed management team was conducting a strategic review to investigate options to restructure the Company's operations. Following completion of the review, the Board has now decided to simplify the ownership of its international distribution partnership network. This is being achieved through the reorganisation of the group's operations in France, Belgium and Luxembourg (the "Territory"), resulting in the divestment today of its 51% owned OTC focused subsidiary, ACM Crawford SAS ("ACM"), to ACM's minority shareholders, Thierry Leveillé and Sebastien Baudinot (the "Minority Shareholders"). ACM will continue to represent the Company as exclusive distributor in the Territory focused on the marketing of York's prescription brands. Background to divestment The Company's 51% interest in ACM was acquired as one of the assets of Derms Development Limited in November 2007. ACM is a sales and marketing business, which has been engaged in selling the Company's products in the Territory and which took prime responsibility for managing the Company's international distributor network. ACM had also developed a range of dermacosmetic products which it marketed principally in France. The various rights and management responsibilities of each of the Company and the Minority Shareholders in relation to ACM were set out in a Shareholders' Agreement entered into at the time of the establishment of the joint ownership and subsequently modified by the parties during 2008 (the "SHA"). The SHA contained provisions creating an obligation on the Company to acquire the outstanding minority interest in ACM of 49% for a pre-agreed aggregate amount of EUR6.25m. The SHA provided that any failure by the Company to complete the acquisition and remit the requisite payments in relation to the minority stake on time would entitle the Minority Shareholders to trigger a call option, enabling them to acquire the Company's 51% shareholding in ACM for a nominal sum of EUR2,550 (representing an amount of EUR10 per share) and to the write off of all intercompany debts owed by ACM to the Company. Divestment of ACM As the next step in implementing the revised corporate strategy, the Company has negotiated and entered into a separation agreement with ACM, the key terms of which are as follows: * An amount of EUR777,000 standing to the balance of an inter-company debt owed by ACM to the Company has, with effect immediately prior to the conduct of the separation, been capitalised through the issuance of 10,500 shares in ACM to the Company; * The Company's aggregate interest in ACM (comprising its initial 51% shareholding together with the additional 10,500 new shares in ACM mentioned above) was acquired as of today by the Minority Shareholders for a total of EUR23,661 in cash; * The balance of all and any intercompany debt owed by ACM to the Company, totalling in aggregate EUR51,795 has been forgiven; * The Company's existing rights and interest in two non-prescription dermacosmetic products, Vitix and Viticolor, have been transferred to ACM; * Any and all interests held by ACM in the prescription product Zindaclin and in the Company's international network of distributors have been transferred to the Company; * The Company has appointed ACM as its exclusive distributor for three years in the Territory; * ACM has granted the Company an option to distribute its products in the US market; and * ACM will provide support for future product acquisitions on a success fee basis. As a result of completing the divestment of its interest in ACM, the Company will be a prescription dermatology and skin care business, selling products directly in the UK market and through an international network of distributors covering 70 countries. Whilst the divestment will result in a lower annual rate of sales for the Company, it is expected to have a minimal impact on the group's results (after accounting for the minority interest) and will save the Company from the requirement to fund the previously agreed purchase price for the minority interest of EUR6.25m. The Company's last set of published results was for the interim period of six months ended on 31 March 2008. The unaudited net assets of ACM at 30 September 2008 were GBP78,811 and its unaudited revenues and loss before taxation for the eleven months ended 30 September 2008 were GBP2,809,189 and GBP191,748 respectively (Source: Company Management Accounts). After careful deliberation, the Directors consider, having consulted with the Company's Nominated Adviser, that the terms of the divestment of ACM are fair and reasonable insofar as its shareholders are concerned. Update on possible offer On 30 March 2009, the Company announced that it had entered into an agreement with Uluru Inc. ("Uluru") under which Uluru has provided the Company with a secured revolving credit facility and on 6 April 2009 the Company further announced that it had also signed a non-binding offer letter with Uluru for Uluru to acquire the Company. Drawdown of the credit facility is required to allow the Company to continue trading through the period needed to complete any formal offer for the Company under the Takeover Code. In accordance with the requirements of the Takeover Panel, Uluru has been notified of the divestment of ACM and has confirmed that, in accordance with Rule 21 of the Takeover Code, it does not consider the divestment to constitute a frustrating action in relation to the current ongoing discussions between the parties. The Board stresses that there can be no certainty that the discussions between the Company and Uluru will lead to an offer being made for the Company. In the event that no offer is made for the Company, it will need to raise additional capital to fund its operating activities and to repay indebtedness in due course. Shareholders should be aware that if the offer is not completed or if the Company's capital raising efforts are unsuccessful, this will have a material adverse effect on the Company's financial position and operations. The Company will provide a further update as and when appropriate. Richard Anderson, Chief Executive of York said: "We are pleased that following the conclusion of this restructuring, the Company will continue to work with ACM in Continental European markets. The settlement which we have negotiated enables us to move forward and exploit fully our international Zindaclin franchise, whilst protecting the Company and its shareholders from the uncertainty which would have arisen as a result of the contractual obligation of the Company to acquire the minority interest becoming due." For more information please contact: +------------------- | York Pharma plc | Tel: +44 (0) 1908 764020 | | Richard Anderson, Chief Executive | | | Officer | | | Ian Miscampbell, Chief Financial | | | Officer | | +------------------- | Collins Stewart Europe Limited | Tel: +44 (0) 207 523 8350 | | Hugh Field / Adam Cowen | | +------------------- | FinnCap | Tel: +44 (0) 207 600 1658 | | Geoff Nash | | +------------------- | Financial Dynamics | Tel: +44 (0) 207 831 3113 | | Ben Brewerton / Emma Thompson | | +------------------- Collins Stewart Europe Limited, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting as Nominated Advisor and broker to York Pharma plc and will not be responsible to anyone other than York Pharma plc for providing the protections afforded to clients of Collins Stewart Europe Limited nor for providing advice in connection with any other matter referred to herein. About York Pharma PLC York Pharma is a pharmaceutical Group, established in 2003, which develops, markets and supplies branded dermatological products to pharmaceutical wholesalers, hospitals and general practitioners within the field of dermatology. | topinfo | |
08/5/2009 16:51 | Come on YRK get some news out you are missing out on one hell of a rally.!!! | topinfo | |
05/5/2009 20:40 | Come on get us shareholders updated, even if its just an explanation whats happening. | topinfo | |
04/5/2009 22:59 | Its so boring waiting for news. | topinfo | |
02/5/2009 07:37 | And still no nobby. | ursamajorra | |
30/4/2009 09:40 | I think 6p we will get maybe slightly more. | topinfo | |
30/4/2009 09:39 | I'm here too. Not much point posting until we get some news. My average is around 14pence, so I'm not expecting to see the majority of that returned. | bignads | |
29/4/2009 21:37 | Steptoe...Cheers mate, but I would have bought in first before giving everyone the heads up...may cost you a premium now. Cheers anyway will have a look. | topinfo | |
29/4/2009 20:56 | There has been some sneaky activities here over the past few years. | topinfo | |
29/4/2009 20:54 | Topinfo lol and half each of the 23% of ULU would be only be fair.I need circa 25p a share to break even so anything would be better than nothing. Hi Kiki14P that's what I keep asking - what ever did happen to Abasol, afterall it was York Pharma (and not Sadler) and I can't remember the last time I heard mention of it!!! | baronyboy | |
29/4/2009 20:52 | Yeah, I just want them to announce offer and re-commence trading so at least I can get some money out of this to put into something else. I hate getting tied down with something like this and its frustrating when it takes so long. However if it takes time so be it as long as they dont say the offer has fallen through and we all lose everything as that doesnt bear thinking about. | topinfo | |
29/4/2009 20:44 | Takeover by ULU is certainly better than any other option so far. Surprised Dr Chris Evans not interested in getting hold of York. | kiki14p | |
29/4/2009 20:43 | So what do you want to see?. Its surely better to accept something rather than nothing? | topinfo | |
29/4/2009 20:43 | So what do you want to see?. Its surely better to accept something rather than nothing? | topinfo | |
29/4/2009 20:42 | Being negative as I hold 5 figures £ and hate being lied to... | kiki14p | |
29/4/2009 20:42 | Kiki....Are you the third shareholder still in that we know about? | topinfo | |
29/4/2009 20:38 | So why are ULU in talks to buy em? It looks as though they are in final process of offer. | topinfo | |
29/4/2009 20:28 | Company has no cash... wasted it all on an acquisition that didn't happen.. nothing left but rubbish and Abasol... what ever happened to that? | kiki14p | |
29/4/2009 20:26 | Why not 6p? | topinfo | |
29/4/2009 20:26 | Why not 6p? | topinfo | |
29/4/2009 20:24 | Be lucky to get 6p imho. | kiki14p | |
29/4/2009 20:22 | BaronyBoy. Yep mate it seems like we are the only two shareholders left, no need to send out circulars just ask us on here do we approve offer...well if its offer of say 6p or bust I will take the 6p. | topinfo |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions